Giapreza
angiotensin II
Table of contents
Overview
Giapreza is a medicine used in adults with dangerously low blood pressure (a condition known as shock).
It is used when other treatments for raising blood pressure have not worked and contains the active substance angiotensin II.
-
List item
Giapreza : EPAR - Medicine overview (PDF/80.09 KB)
First published: 10/10/2019
EMA/370784/2019 -
-
List item
Giapreza : EPAR - Risk-management-plan summary (PDF/239.1 KB)
First published: 10/10/2019
Authorisation details
Product details | |
---|---|
Name |
Giapreza
|
Agency product number |
EMEA/H/C/004930
|
Active substance |
Angiotensin II acetate
|
International non-proprietary name (INN) or common name |
angiotensin II
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
C09
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
PAION Deutschland GmbH
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
23/08/2019
|
Contact address |
Heussstraße 25 |
Product information
23/03/2023 Giapreza - EMEA/H/C/004930 - IAIN/0023
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Agents acting on the renin-angiotensin system
Therapeutic indication
Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.